Embody’s current offer advertises GLP-1 injections from $79 per month and GLP-1 plus GIP injections from $129, with no separate membership or hidden-fee claim. The page also describes clinician review, pharmacy fulfillment and continuing support. Those are the service’s stated features, rather than a completed care experience tested here.
The FAQ adds two practical qualifications: price depends on the selected plan length, and cancellation can take effect in a later cycle if a shipment has already been processed. Those details make the starting advertisement more understandable without inventing a universally flexible monthly plan.
The selected term explains the starting rate
Embody says its price varies across 4-, 12-, 24- and 52-week plan selections. It separately says a change within the same prescribed medication does not raise the price. The two statements concern different dimensions: treatment pricing and purchase commitment.
The $79 starting figure therefore should not become a quote for every duration or medicine. A selected offer needs to identify the total due and term. The cost guide helps distinguish an advertised monthly equivalent from the actual payment arrangement. A clear quote would show the actual initial payment as well as the monthly-looking figure and chosen term.
Clinical approval and delivery are different events
The page describes provider review after intake and any required information, with an additional appointment if more information is needed. Pharmacy fulfillment follows approval. That is a conditional process rather than a guarantee of an immediate prescription or the preferred medicine.
The manufacturer describes state-licensed 503A compounding pharmacy partners and quality testing. This review reports that relationship without claiming a pharmacy audit or authenticated batch result. A dispensing description and an individual professional assessment answer different questions.
The timeline is an expectation story, not a forecast
Embody’s first-six-month presentation describes appetite changes and progress through a sequence of stages. Those statements are marketing expectations, not a measured prediction for the reader. A plausible narrative cannot establish when an individual will notice an effect or how much weight will change.
The page explicitly says compounded medications have not been evaluated or approved by FDA for safety, effectiveness or quality. That qualification belongs with its scientific language. The treatment guide prevents a molecule-level explanation from becoming approval of the actual dispensed preparation.
Cancellation depends on shipment processing
The FAQ says cancellation before the next shipment can avoid the upcoming cycle, but once that shipment has been processed the change begins with the following cycle. Cancel-anytime language should be read alongside that operational boundary. It is not a promise to reverse every charge or shipment.
The SnagRx review has a different term-and-refund qualification, while Trimi explicitly lists annual upfront payment. The renewal guide makes those differences comparable. Embody’s visible strengths are its starting-price and care descriptions; the complete selected commitment remains the important next financial record.
Compare another model
CoreAge Rx · Noom Med · Ro · Found
The invoice guide and product-status guide explain the distinctions behind these entries.
Documents used
Official public information reviewed October 1, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.